Elahere, known by its generic name mirvetuximab soravtansine-gynx, is a medication specifically prescribed for certain types of ovarian cancer in adults. This drug is classified as a biologic and falls under the drug class called antibody-drug conjugates. Elahere is given as an intravenous (IV) infusion typically every 21 days and is approved by the Food and Drug Administration (FDA) for the treatment of ovarian cancer, including cancer of the fallopian tubes and peritoneum in adult patients.
The recommended dosage of Elahere for ovarian cancer treatment is 6 milligrams per kilogram (mg/kg) of adjusted ideal body weight (AIBW). Your doctor will determine your AIBW based on factors such as your weight, height, and other considerations. The infusion of Elahere is administered once every 3 weeks (21 days), and the drug comes in one strength of 100 milligrams per 20 milliliters (mg/mL) of solution (5 mg/mL).
Elahere is given as an IV infusion by a healthcare professional. The infusion process typically takes 1 to 3 hours, and you may receive the treatment in a doctor’s office, infusion center, or hospital. Prior to the Elahere infusion, your doctor will provide other medications to help reduce the risk of infusion-related side effects, such as nausea and vomiting. Examples of these medications include corticosteroids like dexamethasone, antihistamines like diphenhydramine, and fever-reducing medications like acetaminophen.
It is important to note that Elahere is intended to be a long-term treatment for ovarian cancer. Your doctor will discuss your individualized treatment plan with you before starting the medication. If you miss an appointment for your Elahere infusion, contact your doctor’s office promptly to reschedule, as they may need to adjust your dosing schedule accordingly.
Elahere begins to work after your first dose, although you may not physically feel the effects of the drug. Your doctor will closely monitor your progress during treatment to assess the drug’s efficacy in treating your condition. If you have any concerns or questions about your Elahere treatment, be sure to discuss them with your healthcare provider.
The dosage of Elahere for the treatment of ovarian cancer is based on your adjusted ideal body weight and is administered as an IV infusion once every 3 weeks. It is crucial to follow your doctor’s recommendations regarding the dosage and administration of Elahere to optimize its effectiveness in managing your condition. Remember to consult with your healthcare professional before starting any new medication to ensure that it is safe and appropriate for your specific medical needs.